卡塔尔不同祖源人群的癌症遗传易感性:一项基于人群的队列研究
本研究基于卡塔尔基因组计划1期队列的6142名本土卡塔尔人全基因组测序数据,按六个祖源分组分析多基因风险评分及1218个癌症易感基因的罕见致病变异。结果显示乳腺癌、前列腺癌和结直肠癌的多基因风险评分在六个祖源组间存在显著差异(p<0.0001),76人(占6142人的1.2%)携带ClinVar致病或可能致病变异。作者认为可考虑采用分层体系来实施国家癌症预防医学规划。
要点
- 卡塔尔六个祖源组间乳腺癌、前列腺癌和结直肠癌多基因风险评分差异显著(p<0.0001)。
- 76人(6142人中的1.2%)携带ClinVar致病或可能致病的临床可干预癌症基因变异。
- 乳腺癌致病变异在波斯裔中过表达(39名BRCA1/BRCA2变异携带者中22名,56.4%),在阿拉伯半岛裔中完全缺失。
核心结论
- 卡塔尔人群不同祖源间癌症易感基因与多基因风险评分存在高度异质性,作者认为可考虑采用分层体系来实施国家癌症预防医学规划。
研究设计与样本
- 卡塔尔基因组计划1期队列,对2012年12月11日至2016年6月9日由卡塔尔生物样本库招募的6142名本土卡塔尔人DNA样本进行高覆盖度基因组测序,按六个祖源组分层。
- 多基因风险评分在癌症基因组图谱(TCGA)数据集中训练,随后将其分布应用于卡塔尔人群的六个遗传祖源组。
- 分析1218个癌症易感基因内的罕见有害变异,并用ClinVar与CharGer计算工具评估其临床致病性。
主要发现
- 初始数据集含6218名队列参与者,全基因组测序质控过滤后最终数据集为6142份样本。
- 卡塔尔常见癌症的多基因风险评分分析显示六个祖源组间差异显著(p<0.0001)。
- 阿拉伯半岛裔卡塔尔人的结直肠癌多基因风险评分均值最低(-0.41),非洲裔的前列腺癌平均值最高(0.85)。
- 癌症基因罕见变异分析发现76名卡塔尔人(占卡塔尔基因组计划队列6142人的1.2%)携带ClinVar致病或可能致病的临床可干预癌症基因变异。
- 使用CharGer的变异分析识别出195名携带者(占队列的3.17%)。
关键数值与推荐
- 结直肠癌多基因风险评分均值最低为阿拉伯半岛裔(-0.41),前列腺癌平均值最高为非洲裔(0.85)。
- 乳腺癌致病变异在波斯裔卡塔尔人中过表达(39名BRCA1/BRCA2变异携带者中22名,56.4%),在阿拉伯半岛裔中完全缺失。
- ClinVar致病或可能致病变异携带者为76人(占6142人的1.2%);CharGer识别携带者为195人(占队列的3.17%)。
临床怎么用
- 作者认为可考虑采用分层体系来实施国家癌症预防医学规划。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disparities in the genetic risk of cancer among various ancestry groups and populations remain poorly defined. This challenge is even more acute for Middle Eastern populations, where the paucity of genomic data could affect the clinical potential of cancer genetic risk profiling. We used data from the phase 1 cohort of the Qatar Genome Programme to investigate genetic variation in cancer-susceptibility genes in the Qatari population. METHODS: The Qatar Genome Programme generated high-coverage genome sequencing on DNA samples collected from 6142 native Qataris, stratified into six distinct ancestry groups: general Arab, Persian, Arabian Peninsula, Admixture Arab, African, and South Asian. In this population-based, cohort study, we evaluated the performance of polygenic risk scores for the most common cancers in Qatar (breast, prostate, and colorectal cancers). Polygenic risk scores were trained in The Cancer Genome Atlas (TCGA) dataset, and their distributions were subsequently applied to the six different genetic ancestry groups of the Qatari population. Rare deleterious variants within 1218 cancer susceptibility genes were analysed, and their clinical pathogenicity was assessed by ClinVar and the CharGer computational tools. FINDINGS: The cohort included in this study was recruited by the Qatar Biobank between Dec 11, 2012, and June 9, 2016. The initial dataset comprised 6218 cohort participants, and whole genome sequencing quality control filtering led to a final dataset of 6142 samples. Polygenic risk score analyses of the most common cancers in Qatar showed significant differences between the six ancestry groups (p<0·0001). Qataris with Arabian Peninsula ancestry showed the lowest polygenic risk score mean for colorectal cancer (-0·41), and those of African ancestry showed the highest average for prostate cancer (0·85). Cancer-gene rare variant analysis identified 76 Qataris (1·2% of 6142 individuals in the Qatar Genome Programme cohort) carrying ClinVar pathogenic or likely pathogenic variants in clinically actionable cancer genes. Variant analysis using CharGer identified 195 individuals carriers (3·17% of the cohort). Breast cancer pathogenic variants were over-represented in Qataris of Persian origin (22 [56·4%] of 39 BRCA1/BRCA2 variant carriers) and completely absent in those of Arabian Peninsula origin. INTERPRETATION: We observed a high degree of heterogeneity for cancer predisposition genes and polygenic risk scores across ancestries in this population from Qatar. Stratification systems could be considered for the implementation of national cancer preventive medicine programmes. FUNDING: Qatar Foundation.
引用
- Saad M, Mokrab Y, Halabi N, et al. Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study. Lancet Oncol. 2022. PMID: 35150601. doi:10.1016/S1470-2045(21)00752-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。